Radiopharmaceuticals

Precision Peptide Conjugates for Radionuclide Delivery

Orbit Discovery’s platform excels at discovering and optimizing peptide conjugates for precise radionuclide delivery.
‍
Using our bead-based technology and flow cytometry, we quickly identify peptides with strong affinity for tumor-specific targets.Our system generates diverse peptide libraries, allowing us to screen for binders to challenging targets like tumor antigens. This results in peptide conjugates that enhance therapeutic precision and minimize side effects.

With flexible design options and advanced screening, Orbit Discovery accelerates the development of peptide conjugates for radionuclide therapies

Features

High Affinity for Tumor Specific Targets

‍
Discover and optimize peptide conjugates with high affinity for tumor-specific cell surface markers, ensuring accurate radionuclide delivery.

Massive Library Diversity

‍
Build superlarge peptide libraries tailored for radionuclide delivery, offering a wide array of chemistries, structures, and affinities.

Streamlined Conjugate Development

‍
Accelerate the discovery process with FACS-based screening, identifying and refining low affinity binders in for fast optimization.

From Hit to Lead

‍
Opitimise and expand your hit with access to Orbit's peptide chemistry expertise. Screen for peptides that internalise, test chelators, linkers and determine key binding motifs to turn your hit peptide to a lead.